[Pharmacokinetics of adriamycin vaginal suppository in uterine cervical cancer].
Vaginal suppositories of Adriamycin (ADM, 5 mg), for reducing the capacity for repair from sublethal damage of X-ray-irradiated cells, were prepared using Wipepsol S-55 as the vehicle, and were intravaginally administered to patients with advanced uterine cervical cancer, and their pharmacokinetics and clinical effects were studied. The ADM concentration in the uterine cervical cancer tissues indicated high levels (17 to 566 micrograms/g), and migration into the cardinal ligament and regional lymph nodes was noted. However, little ADM was detected in serum (0 to 0.14 micrograms/g), probably because of its molecular weight and excellent tissue absorbance, and no side effects, such as cardiotoxicity and myelosuppression due to consecutive administration were detected. Histologically, the effect obtained when administered alone was limited, administration in combination with radiotherapy being more effective. Accordingly, radiotherapy of advanced uterine cervical cancer with concomitant administration of ADM vaginal suppositories seems to bring about a more powerful antitumoral effect with fewer systemic side effects.
D002584:Cervix Uteri / Q000378:metabolism / Q000473:pathology; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D013488:Suppositories; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D014621:Vagina / Q000378:metabolism / Q000473:pathology
D013488:Suppositories; D004317:Doxorubicin